Invitae is in a post-confirmation wind-down, with claims reconciliation and distributions continuing under a plan effective August 7, 2024. The October 2026 report Dkt. 1292 anticipates an application for a final decree by December 31, 2027; the claims-objection deadline notice Dkt. 1276 extends that deadline through February 1, 2027.

Invitae Corporation is in a post-confirmation wind-down under a Chapter 11 plan that became effective on August 7, 2024, following its February 13, 2024 petition. The plan effectiveness notice Dkt. 927 records confirmation and effectiveness; the October 2026 post-confirmation report Dkt. 1292 identifies Andrew Spirito as plan administrator and anticipates an application for a final decree by December 31, 2027.

The genetic testing company entered bankruptcy after an acquisition-driven expansion increased its debt and operating costs despite subsequent cost reductions. The disclosure statement Dkt. 472 reported approximately $1,482.5 million in total debt obligations at the petition date, including secured and unsecured notes. The court authorized the use of cash collateral under a final order Dkt. 188 and, on May 7, 2024, approved a $239 million sale of acquired assets to Labcorp Genetics Inc. under the sale order Dkt. 463.

The October 2026 report Dkt. 1292 lists cumulative payments of $303,129,909 on secured claims and $4,000,000 on general unsecured claims. It says claims reconciliation and objections remain ongoing and that projected recoveries depend on receivables, retained causes of action and resolution of the committee appeal. The claims-objection deadline notice Dkt. 1276 extends the deadline through February 1, 2027.

A separate dispute concerns an Illinois genetic privacy action against Invitae and Labcorp. The wind-down debtors seek to enforce the plan and sale order against the action, while B.W., the plaintiff, contends that the alleged disclosure occurred after plan effectiveness and is not released. Following argument, B.W. requested answers or limited discovery about the timing of the alleged data transfer in a September 2026 supplemental statement Dkt. 1288; the debtors’ position appears in their reply Dkt. 1285.

Invitae is in a post-confirmation wind-down, with claims reconciliation and distributions continuing under a plan effective August 7, 2024. The October 2026 report Dkt. 1292 anticipates an application for a final decree by December 31, 2027; the claims-objection deadline notice Dkt. 1276 extends that deadline through February 1, 2027.

Invitae Corporation is in a post-confirmation wind-down under a Chapter 11 plan that became effective on August 7, 2024, following its February 13, 2024 petition. The plan effectiveness notice Dkt. 927 records confirmation and effectiveness; the October 2026 post-confirmation report Dkt. 1292 identifies Andrew Spirito as plan administrator and anticipates an application for a final decree by December 31, 2027.

The genetic testing company entered bankruptcy after an acquisition-driven expansion increased its debt and operating costs despite subsequent cost reductions. The disclosure statement Dkt. 472 reported approximately $1,482.5 million in total debt obligations at the petition date, including secured and unsecured notes. The court authorized the use of cash collateral under a final order Dkt. 188 and, on May 7, 2024, approved a $239 million sale of acquired assets to Labcorp Genetics Inc. under the sale order Dkt. 463.

The October 2026 report Dkt. 1292 lists cumulative payments of $303,129,909 on secured claims and $4,000,000 on general unsecured claims. It says claims reconciliation and objections remain ongoing and that projected recoveries depend on receivables, retained causes of action and resolution of the committee appeal. The claims-objection deadline notice Dkt. 1276 extends the deadline through February 1, 2027.

A separate dispute concerns an Illinois genetic privacy action against Invitae and Labcorp. The wind-down debtors seek to enforce the plan and sale order against the action, while B.W., the plaintiff, contends that the alleged disclosure occurred after plan effectiveness and is not released. Following argument, B.W. requested answers or limited discovery about the timing of the alleged data transfer in a September 2026 supplemental statement Dkt. 1288; the debtors’ position appears in their reply Dkt. 1285.